Literature DB >> 18779049

Structural insights into the mechanisms of antibody-mediated neutralization of flavivirus infection: implications for vaccine development.

Theodore C Pierson1, Daved H Fremont, Richard J Kuhn, Michael S Diamond.   

Abstract

Flaviviruses are a group of small RNA viruses that cause severe disease in humans worldwide and are the target of several vaccine development programs. A primary goal of these efforts is to elicit a protective humoral response directed against the envelope proteins arrayed on the surface of the flavivirus virion. Advances in the structural biology of these viruses has catalyzed rapid progress toward understanding the complexity of the flavivirus immunogen and the molecular basis of antibody-mediated neutralization. These insights have identified factors that govern the potency of neutralizing antibodies and will inform the design and evaluation of novel vaccines.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18779049      PMCID: PMC2678546          DOI: 10.1016/j.chom.2008.08.004

Source DB:  PubMed          Journal:  Cell Host Microbe        ISSN: 1931-3128            Impact factor:   21.023


  78 in total

1.  Monoclonal antibody mapping of the envelope glycoprotein of the dengue 2 virus, Jamaica.

Authors:  J T Roehrig; R A Bolin; R G Kelly
Journal:  Virology       Date:  1998-07-05       Impact factor: 3.616

2.  Effectiveness of live-attenuated Japanese encephalitis vaccine (SA14-14-2): a case-control study.

Authors:  S Hennessy; Z Liu; T F Tsai; B L Strom; C M Wan; H L Liu; T X Wu; H J Yu; Q M Liu; N Karabatsos; W B Bilker; S B Halstead
Journal:  Lancet       Date:  1996-06-08       Impact factor: 79.321

3.  Proteolytic activation of tick-borne encephalitis virus by furin.

Authors:  K Stadler; S L Allison; J Schalich; F X Heinz
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

4.  Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity.

Authors:  D W Vaughn; S Green; S Kalayanarooj; B L Innis; S Nimmannitya; S Suntayakorn; T P Endy; B Raengsakulrach; A L Rothman; F A Ennis; A Nisalak
Journal:  J Infect Dis       Date:  2000-01       Impact factor: 5.226

5.  Characterization of dengue virus complex-specific neutralizing epitopes on envelope protein domain III of dengue 2 virus.

Authors:  Gregory D Gromowski; Nicholas D Barrett; Alan D T Barrett
Journal:  J Virol       Date:  2008-06-18       Impact factor: 5.103

Review 6.  Global spread and persistence of dengue.

Authors:  Jennifer L Kyle; Eva Harris
Journal:  Annu Rev Microbiol       Date:  2008       Impact factor: 15.500

7.  Loss of active neuroinvasiveness in attenuated strains of West Nile virus: pathogenicity in immunocompetent and SCID mice.

Authors:  M Halevy; Y Akov; D Ben-Nathan; D Kobiler; B Lachmi; S Lustig
Journal:  Arch Virol       Date:  1994       Impact factor: 2.574

8.  Neutralizing F(ab')2 fragments of protective monoclonal antibodies to yellow fever virus (YF) envelope protein fail to protect mice against lethal YF encephalitis.

Authors:  J J Schlesinger; S Chapman
Journal:  J Gen Virol       Date:  1995-01       Impact factor: 3.891

9.  Antibodies that block virus attachment to Vero cells are a major component of the human neutralizing antibody response against dengue virus type 2.

Authors:  R T He; B L Innis; A Nisalak; W Usawattanakul; S Wang; S Kalayanarooj; R Anderson
Journal:  J Med Virol       Date:  1995-04       Impact factor: 2.327

Review 10.  Dengue and dengue hemorrhagic fever.

Authors:  D J Gubler
Journal:  Clin Microbiol Rev       Date:  1998-07       Impact factor: 26.132

View more
  144 in total

1.  Examining the cross-reactivity and neutralization mechanisms of a panel of mAbs against adeno-associated virus serotypes 1 and 5.

Authors:  Carole E Harbison; Wendy S Weichert; Brittney L Gurda; John A Chiorini; Mavis Agbandje-McKenna; Colin R Parrish
Journal:  J Gen Virol       Date:  2011-11-09       Impact factor: 3.891

2.  Protection from secondary dengue virus infection in a mouse model reveals the role of serotype cross-reactive B and T cells.

Authors:  Simona Zompi; Brian H Santich; P Robert Beatty; Eva Harris
Journal:  J Immunol       Date:  2011-11-30       Impact factor: 5.422

3.  Influence of pr-M cleavage on the heterogeneity of extracellular dengue virus particles.

Authors:  Jiraphan Junjhon; Thomas J Edwards; Utaiwan Utaipat; Valorie D Bowman; Heather A Holdaway; Wei Zhang; Poonsook Keelapang; Chunya Puttikhunt; Rushika Perera; Paul R Chipman; Watchara Kasinrerk; Prida Malasit; Richard J Kuhn; Nopporn Sittisombut
Journal:  J Virol       Date:  2010-06-02       Impact factor: 5.103

4.  Immunodominance and functional activities of antibody responses to inactivated West Nile virus and recombinant subunit vaccines in mice.

Authors:  Juergen Zlatkovic; Karin Stiasny; Franz X Heinz
Journal:  J Virol       Date:  2010-12-08       Impact factor: 5.103

5.  Structural basis for Zika envelope domain III recognition by a germline version of a recurrent neutralizing antibody.

Authors:  Shannon R Esswein; Harry B Gristick; Andrea Jurado; Avery Peace; Jennifer R Keeffe; Yu E Lee; Alisa V Voll; Mohsan Saeed; Michel C Nussenzweig; Charles M Rice; Davide F Robbiani; Margaret R MacDonald; Pamela J Bjorkman
Journal:  Proc Natl Acad Sci U S A       Date:  2020-04-22       Impact factor: 11.205

6.  Recombinant dengue type 2 viruses with altered e protein domain III epitopes are efficiently neutralized by human immune sera.

Authors:  Wahala M P B Wahala; Claire Huang; Siritorn Butrapet; Laura J White; Aravinda M de Silva
Journal:  J Virol       Date:  2012-01-25       Impact factor: 5.103

7.  A hydrogen peroxide-inactivated virus vaccine elicits humoral and cellular immunity and protects against lethal West Nile virus infection in aged mice.

Authors:  Amelia K Pinto; Justin M Richner; Elizabeth A Poore; Pradnya P Patil; Ian J Amanna; Mark K Slifka; Michael S Diamond
Journal:  J Virol       Date:  2012-12-05       Impact factor: 5.103

8.  Dengue virus neutralization is modulated by IgG antibody subclass and Fcgamma receptor subtype.

Authors:  W W Shanaka I Rodrigo; Olivia K T Block; Christopher Lane; Soila Sukupolvi-Petty; Ana P Goncalvez; Syd Johnson; Michael S Diamond; Ching-Juh Lai; Robert C Rose; Xia Jin; Jacob J Schlesinger
Journal:  Virology       Date:  2009-10-14       Impact factor: 3.616

9.  Complement protein C1q reduces the stoichiometric threshold for antibody-mediated neutralization of West Nile virus.

Authors:  Erin Mehlhop; Steevenson Nelson; Christiane A Jost; Sergey Gorlatov; Syd Johnson; Daved H Fremont; Michael S Diamond; Theodore C Pierson
Journal:  Cell Host Microbe       Date:  2009-10-22       Impact factor: 21.023

10.  A Single Amino Acid Substitution in the M Protein Attenuates Japanese Encephalitis Virus in Mammalian Hosts.

Authors:  Mélissanne de Wispelaere; Cécile Khou; Marie-Pascale Frenkiel; Philippe Desprès; Nathalie Pardigon
Journal:  J Virol       Date:  2015-12-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.